Having trouble accessing articles? Reset your cache.

Tasocitinib: Phase II data

A double-blind, dose-ranging Phase II trial in 197 patients showed that all 3 doses of oral tasocitinib met the primary endpoint of a significantly greater proportion of patients achieving a PASI 75 response at week 12 vs. placebo. Specifically,

Read the full 391 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE